Free Trial
NASDAQ:OPCH

Option Care Health Q3 2026 Earnings Report

Option Care Health logo
$31.06 +0.06 (+0.18%)
As of 01:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Option Care Health EPS Results

Actual EPS
N/A
Consensus EPS
$0.49
Beat/Miss
N/A
One Year Ago EPS
N/A

Option Care Health Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.48 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Option Care Health Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call Date
Thursday, October 29, 2026
Conference Call Time
8:30AM ET

Conference Call Resources

Option Care Health Earnings Headlines

Mid Cap Stocks To Research - October 6th
NNVC Is Heading Into a Big Moment
NanoViricides (NYSE American: NNVC) is moving NV-387 into a Phase II trial for Ebola in the Democratic Republic of Congo, where the Bundibugyo ebolavirus outbreak carries a crude fatality rate above 48 percent. NV-387 is being tested as an oral antiviral, a potential edge over infusion-based treatments. The candidate also holds FDA Orphan Drug and Rare Pediatric Disease designations for measles, giving the platform a second clinical pathway.tc pixel
Option Care: Booking My Gains Ahead Of Deal Completion
See More Option Care Health Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Option Care Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Option Care Health and other key companies, straight to your email.

About Option Care Health

Option Care Health (NASDAQ:OPCH) (NASDAQ: OPCH) is a provider of home and alternate-site infusion services in the United States. The company works with patients, physicians, hospitals, health plans and pharmaceutical manufacturers to deliver and manage infusion therapy outside traditional hospital settings, including in patients’ homes, ambulatory infusion suites and other community-based locations.

Its services include the provision and administration of specialty medications and other infusion therapies for conditions such as infections, immune disorders, chronic diseases and nutritional deficiencies. Option Care Health also provides nursing support, clinical monitoring, patient education, care coordination and pharmacy services designed to support treatment adherence and help patients transition from hospital care to home-based therapy.

The company was formed through the combination of Option Care and BioScrip, which completed in 2019, and adopted the Option Care Health name in 2020. It serves patients across the United States through a nationwide network of pharmacies, infusion centers and clinical professionals. John C. Rademacher serves as the company’s president and chief executive officer.

View Option Care Health Profile